98%
921
2 minutes
20
Background: Diagnosis and treatment of primary lung adenocarcinoma in children remains challenging given its rarity. Here we highlight the clinical history, pathological evaluation, genomic findings, and management of a very young patient with metastatic lung adenocarcinoma.
Case Presentation: A 10-year-old white girl presented with brain metastases due to primary pulmonary adenocarcinoma. Next generation sequencing analysis with "Comprehensive Cancer Panel" highlighted the presence of multiple non-targetable mutations in the FLT4, UBR5, ATM, TAF1, and GUCY1A2 genes. She was treated aggressively with chemotherapy, surgery, and radiation therapy for local and distant recurrence. Eventually, therapy with nivolumab was started compassionately, and she died 23 months after diagnosis.
Conclusions: Extremely rare cancers in children such as lung adenocarcinoma need accurate and specific diagnosis in order to develop an optimal plan of treatment. It is also necessary to underline that "children are not little adults," thus implying that an adult-type cancer in the pediatric population might have a different etiopathogenesis. Diagnostic confirmation and primary treatment of such rare conditions should be centralized in reference centers, collaborative networks, or both, with multidisciplinary approaches and very specific expertise.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119591 | PMC |
http://dx.doi.org/10.1186/s13256-018-1781-1 | DOI Listing |
J Thorac Oncol
August 2025
Department of Radiation Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Introduction: Cigarette smoking negatively affects lung cancer prognosis. Incorporating smoking history into stage-stratified survival analyses may improve prognostication.
Methods: Using the International Association for the Study of Lung Cancer ninth edition NSCLC database, we evaluated the association between smoking status at diagnosis and overall survival (OS) using Kaplan-Meier plots and multivariate Cox proportional hazard regression models adjusted for age, region, sex, histologic type, performance status, and TNM stage.
Brief Bioinform
August 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an 710004, China.
Accurate tumor mutation burden (TMB) quantification is critical for immunotherapy stratification, yet remains challenging due to variability across sequencing platforms, tumor heterogeneity, and variant calling pipelines. Here, we introduce TMBquant, an explainable AI-powered caller designed to optimize TMB estimation through dynamic feature selection, ensemble learning, and automated strategy adaptation. Built upon the H2O AutoML framework, TMBquant integrates variant features, minimizes classification errors, and enhances both accuracy and stability across diverse datasets.
View Article and Find Full Text PDFCureus
August 2025
Pulmonology, Unidade Local de Saúde (ULS) da Guarda, Guarda, PRT.
Pulmonary atypical adenomatous hyperplasia (AAH) is a recognized precursor lesion to pulmonary adenocarcinoma (ADC). We present the case of a 79-year-old ex-smoker in whom transthoracic needle biopsy revealed histological features suggestive of lung ADC. However, surgical resection of the lesion later demonstrated only AAH.
View Article and Find Full Text PDFCytotechnology
October 2025
Department of Traditional Chinese Medicine Pharmacy, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, No. 168, Hongkong Road, Jiangan District, Wuhan, 430014 Hubei China.
Unlabelled: Oxymatrine is a quinolizidine alkaloid derived from roots that has demonstrated significant antitumor activity against various cancers, including lung cancer. Recently, combination therapies involving anticancer agents and targeted interventions for dysregulated genes have emerged as a promising strategy to enhance treatment efficacy and overcome drug resistance. This study investigates the synergistic effects of oxymatrine and GIMAP8 in modulating the progression of lung adenocarcinoma (LUAD).
View Article and Find Full Text PDF